Home » KEYNOTE-564: Favorable Long-Term Safety With Adjuvant Pembrolizumab in RCC

KEYNOTE-564: Favorable Long-Term Safety With Adjuvant Pembrolizumab in RCC

by Naomi Haas, MD | Jun 18, 2025 | Articles | 0 Comments